Skip to playerSkip to main content
  • 2 days ago
Pharma companies Merck and Moderna have announced that their personalised mRNA cancer vaccine, combined with the immunotherapy drug Keytruda, has cleared phase three human trials for melanoma. This marks the first time an individualised cancer vaccine built from a patient's own tumour mutations has succeeded at the final stage of testing. The vaccine works by training the immune system to recognise and target specific genetic markers, helping delay cancer recurrence and preventing its spread to other organs. The trial involved 1,137 high-risk melanoma patients across stages two B to four. Moderna's chief executive officer highlighted the development as a major breakthrough, noting that mRNA technology could potentially be adapted for other cancers, including lung, kidney, and bladder cancer.

Category

🗞
News
Transcript
00:00Now to a story that could redefine how the world fights cancer.
00:05Pharma giants Merck and Moderna have announced that their personalized mRNA cancer vaccine
00:12that has cleared phase 3 human trials for melanoma.
00:15And this will be the first time an individualized cancer vaccine built entirely from the patient's own tumor
00:23has succeeded at its final stage of testing.
00:26Combined with the immunotherapy drug, which is Keytruda.
00:30The vaccine has shown it can delay cancer from returning and also stop it from spreading to other organs.
00:37But what exactly does it do? How does it do it?
00:42And why should it matter to people even beyond the melanoma?
00:47Why is Moderna's own CEO calling this the biggest moment as big as COVID vaccine?
00:53Let's break it down.
00:56Now four letters, four letters that could change how cancer is treated in this country.
01:02And those are MRNA.
01:04This is the tech, which is not to remember.
01:07But, you know, we've seen this before in the COVID vaccines and some other cases as well.
01:11But this is now being used by Moderna and Merck for melanoma.
01:15And this could change the way the world treats cancer.
01:19So what exactly is this technology?
01:21Let's break it down because it's genuinely fascinating.
01:23Now imagine somebody who has just had a tumor, surgically removed it, and that tumor goes for a biopsy.
01:31From that biopsy, the doctors take out the sample and read its mutations, a specific genetic marker unique to that
01:38person's cancer.
01:39Those markers are then coded into a vaccine, and that vaccine is injected back into the patient's body.
01:46Not to attack cancer directly with chemicals, but to train your own immune system and recognize and fight it.
01:55It's personalization of medicine in the truest sense.
02:00It's like your own personal AI fighting the cancer that your body otherwise could not.
02:06This is built entirely around one person's own tumor.
02:10Combined with Getruda, remember, the immunotherapy drug already used in melanoma treatment.
02:15This vaccine does two things, like I said.
02:18It helps delay the cancer from returning, and it also helps stop it from spreading to other organs.
02:25Now, does this sound like a game changer?
02:28Well, it does.
02:28But let's look at what the actual trial data tells us.
02:32The trial has been done on 1,137 high-risk melanoma patients who were part of the phase 3 trials,
02:41all the way spanning from stage 2b, all the way to stage 4.
02:45The results have been promising, but the exact percentages have not been made public yet.
02:50The company is saving those for presentations before medical peers and regulatory bodies.
02:55But what about side effects?
02:57Well, the company is not saying anything major so far.
03:01They've reported fatigue, chills, and pain at the injection site as one of those side effects being reported.
03:09And the markers have already reacted.
03:13Now, the Moderna's shares there have jumped over 100% in a single day of trade right after the announcement
03:22was made on the successful phase 3 trial of this vaccine.
03:26The biggest, biggest day gain that we've seen in the company's history, a sign of just how significant investors believe
03:35this breakthrough could be.
03:36And now, here is why this matters to all of us, even those whose cancer goes beyond melanoma.
03:46Moderna's CEO has called this as big as the moment of COVID vaccine breakthrough.
03:49And that is because scientists believe that if this technology works on melanoma, works for melanoma, the same could be
03:57used in other kinds of cancers as well.
04:00For example, lung, for example, kidney, for example, bladder cancer as well.
04:04The possibilities are endless.
04:07And that is what makes this breakthrough so exciting, especially when you consider that the American Cancer Society has already
04:16estimated the numbers.
04:18Let me jog your memory there.
04:19According to the American Cancer Society, every second man and every third woman is likely to develop cancer in their
04:28lifetime.
04:28And that's a number that is a scary one.
04:31So this can, this entire vaccine comes as a huge ray of hope with numbers like this and personalized vaccine
04:38approach now showing great results.
04:40This space is worth watching out for and some great breakthroughs are only in the pipeline.
Comments

Recommended